预约演示
更新于：2025-10-30
Etonogestrel
依托孕烯
更新于：2025-10-30
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2006-07-17), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C22H28O2 |
InChIKeyGCKFUYQCUCGESZ-BPIQYHPVSA-N |
CAS号54048-10-1 |
关联
73
项与 依托孕烯 相关的临床试验NCT07201402
Prospective Long-term Study of Etonogestrel Contraceptive Implant Insertion at an Alternative Scapular Site
CTRI/2024/08/072277
A Multi-Center, Open-Label, Randomized, Single Dose, Parallel Design, In Vivo/Ex Vivo Pharmacokinetic study of LSP-9759 (etonogestrel implant, 68 mg) and Nexplanon®, etonogestrel implant, 68 mg in Healthy Female Participants - NIL
CTIS2025-520736-41-00
- BLCL-ETN-ANV-01
100 项与 依托孕烯 相关的临床结果
登录后查看更多信息
100 项与 依托孕烯 相关的转化医学
登录后查看更多信息
100 项与 依托孕烯 相关的专利（医药）
登录后查看更多信息
1,117
项与 依托孕烯 相关的文献（医药）2025-11-01JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY
Ultrasound-Guided Removal of Nonpalpable Subcutaneous Implanted Contraceptive (Implanon)
Article
作者: Mnatzakanian, Aren ; Alkhattab, Maha ; O'Sullivan, Gerard ; Dhannoon, Amenah
Implantable progestin-only contraceptives such as Implanon (Organon International, Jersey City, New Jersey) have grown in popularity and are recommended as first-line contraception for women. In rare cases, implants may migrate or become impalpable, requiring localization prior to open removal by plastic surgery or minimally invasive image-guided removal by interventional radiology (IR). A retrospective review of ultrasound (US)-guided Implanon removals within the IR department of a single center between 2010 and 2020 was performed to report on procedure outcomes, including technical success and adverse event rates. The procedure was performed in 115 women with a technical success rate of 95%. The mean duration of the procedure was 14 minutes (SD ± 3.6). Only 1 patient experienced postprocedural fingertip pain and paresthesia, which resolved spontaneously. IR offers an excellent option for minimally invasive US-guided removal of Implanon devices complicated by implant migration, with a high technical success rate and patient satisfaction and low adverse event rate.
2025-10-01JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
Evaluation of reference ranges of four circulating sex steroids from dried blood spots in women aged 18-40 years
Article
作者: Desai, Reena ; Davis, Susan R ; Wang, Yuanyuan ; Gialouris, Josh ; Handelsman, David J
Capillary dried blood spot collection offers an excellent less invasive alternative to serum or plasma collection by venesection. This study aimed to generate reference ranges for four sex steroids in capillary whole blood samples collected from healthy premenopausal women as dried blood spots as a screening method to detect disorders of sex development. Using this method we evaluated variations according to age, body mass index, menstrual cycle, and hormonal contraceptive use. This cross-sectional, community-based study included 120 healthy premenopausal women aged 18-40 years, not pregnant or breastfeeding. Whole blood testosterone (T), androstenedione (A4), 17α hydroxyprogesterone (17OHP), and progesterone (P4) were measured by liquid chromatography-tandem mass spectrometry (LCMS) from dried filter paper blood spots. The median (95 % confidence limits) for T were 0.75 (0.28, 2.20) nmol/L, A4 2.69 (1.02, 6.03) nmol/L, 17OHP 1.62 (0.32, 8.52) nmol/L and P4 0.65 (0.18, 41.0) nmol/L. Age by 5-year interval was associated with a progressive reduction in A4 but not for other steroids. Menstrual variation was evident for 17OHP and P4 with increases in luteal phase with a small mid-cycle peak for A4 but no other consistent changes. All sex steroid concentrations were significantly lower in participants taking a systemic hormonal contraceptive (combined oral contraceptive or etonogestrel implant). None of the sex steroid concentrations varied significantly with body mass index. These data provide reference ranges for whole blood T, A4, 17OHP and P4 measured by LCMS from dried blood spots from healthy young adult premenopausal women. Small but significant variations were evident according to age, hormonal contraceptive use and menstrual cycle phase.
2025-10-01AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
Breastfeeding after immediate vs delayed postpartum contraceptive implant placement: a noninferiority randomized controlled trial
Article
作者: Krashin, Jamie W ; Petersen, Timothy R ; Alcantara, Jasmin ; Bulleit, Erin ; Sanchez, Dominique ; Bender, Emily ; Turok, David K ; Espey, Eve ; Leeman, Lawrence ; Black, Patricia ; Trujillo, Victoria Y ; Carroll, Smita ; Rivera-Montalvo, Maritza
BACKGROUND:
Breastfeeding and access to contraception are important to patient and public health. The etonogestrel contraceptive implant is a popular and highly effective long-acting progestin contraceptive with few medical contraindications. Despite theoretical concern about early exogenous progestin exposure inhibiting lactogenesis, previous studies showed reassuring lactogenesis and long-term breastfeeding with immediate placement. However, no studies compare placement within 24 hours postpartum to delayed placement at a postpartum visit.
OBJECTIVE:
We studied the association between etonogestrel contraceptive implant placement within 24 hours vs at least 2 weeks postpartum and breastfeeding continuation at 8 weeks postpartum.
STUDY DESIGN:
We conducted a noninferiority randomized controlled trial of postpartum participants who planned to breastfeed and use the etonogestrel implant at 2 university hospitals in the Mountain West. Participants were at least 13 years old, fluent in English or Spanish, had term deliveries, and lacked contraindications to implant use. They were randomized 1:1 to implant placement within 24 hours or at least 2 weeks postpartum. We collected baseline participant characteristics from chart review and questionnaires. Participants reported breastfeeding status and implant use via electronic questionnaires at 2, 4, 8, 12, and 24 weeks postpartum. The study was powered to assess a 15% noninferiority margin between groups of the primary outcome, any breastfeeding at 8 weeks in the per protocol population.
RESULTS:
We enrolled 150 participants (n=78 immediate, n=72 delayed). After removing participants who declined implant placement, withdrew, or were ineligible (n=8) or lacked primary outcome data (n=16), the modified intention-to-treat analysis included 126 participants (n=69 immediate, n=57 delayed). The per protocol analysis included 115 participants (n=62 immediate, n=53 delayed) after excluding additional participants who received the implant outside of the placement timing windows (n=11). Participants were similar in age, race, and ethnicity, as well as previous breastfeeding experience, delivery mode, and epidural use; the delayed group reported prior implant use less frequently (29% vs 43%). In the per protocol analysis, 77.4% (48/62) of participants in the immediate group and 81.1% (43/53) in the delayed group reported any breastfeeding at 8 weeks; the lower limit of the one-sided 95% confidence interval around this -3.7% difference was -16%, exceeding our predefined noninferiority margin. The difference between groups in the modified intention-to-treat group was smaller (-0.6%) and within the noninferiority margin (-12.8% lower limit of the 1-sided 95% confidence interval): 78.3% (54/69) immediate and 78.9% (45/57) delayed. Implant continuation at 24 weeks trended toward favoring immediate placement (96%, 52/54) compared to in those assigned to delayed placement, (85%, 39/46, P=.08). Exclusive or any breastfeeding and implant continuation through 24 weeks were similar between groups.
CONCLUSION:
The results demonstrated no clinically important differences in breastfeeding and implant continuation outcomes though our primary outcome exceeded our predefined noninferiority margin. These reassuring data add to the evidence base for supporting etonogestrel implant initiation for breastfeeding people whenever they desire it postpartum.
100 项与 依托孕烯 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 麻醉 | 加拿大 | 2020-07-15 | |
| 避孕 | 美国 | 2006-07-17 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 痛经 | 临床2期 | - | 2013-01-21 | |
| 原发性痛经 | 临床2期 | - | 2013-01-21 | |
| 出血 | 临床2期 | - | 2009-11-01 | |
| 下尿路症状 | 临床2期 | - | 2008-03-01 | |
| 前列腺增生症 | 临床2期 | - | 2008-03-01 | |
| 前列腺增生症 | 临床2期 | - | 2008-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 110 | (Group 1 DOR + ETG) | 衊醖蓋範蓋淵構憲壓製(鑰範襯襯壓簾積窪繭願) = 網襯獵顧鹹鹽憲艱製蓋 廠範憲鹽範範壓壓遞範 (網選積選醖鬱繭範鏇觸, 餘獵繭糧襯淵齋鑰網壓 ~ 鏇膚艱繭夢繭繭鬱膚範) 更多 | - | 2025-04-08 | ||
(Group 2 DOR + IM DMPA) | 衊醖蓋範蓋淵構憲壓製(鑰範襯襯壓簾積窪繭願) = 網膚願艱淵淵淵襯繭遞 廠範憲鹽範範壓壓遞範 (網選積選醖鬱繭範鏇觸, 齋繭廠製鏇鑰鑰壓齋選 ~ 憲膚鑰簾觸餘網鹹齋網) 更多 | ||||||
临床2期 | 获得性免疫缺陷综合征 | 避孕 | 72 | (Standard Dose Etonogestrel Implant) | 醖選鏇廠艱繭積窪遞窪 = 觸積鹹艱鹽襯齋遞願齋 簾遞鹽襯顧遞簾襯憲遞 (夢獵觸鹹範鹹廠鬱獵蓋, 鑰齋顧簾餘顧簾艱範積 ~ 鏇構淵構糧膚簾繭網蓋) 更多 | - | 2024-09-05 | |
(Increased Dose Etonogestrel Implant) | 醖選鏇廠艱繭積窪遞窪 = 範鹽構願鬱積製鹽淵鹽 簾遞鹽襯顧遞簾襯憲遞 (夢獵觸鹹範鹹廠鬱獵蓋, 壓蓋鬱鬱齋鹹簾夢膚鏇 ~ 艱廠鏇鏇膚鹽蓋遞襯鏇) 更多 | ||||||
临床2期 | - | Double Etonogestrel Implant | 遞膚選夢糧選齋夢鹹構(餘膚夢觸齋襯選範淵願) = 鹽構壓鏇鏇醖鑰齋壓醖 憲鬱窪鏇蓋鹹選糧淵選 (襯構獵窪壓醖餘餘鬱餘 ) | - | 2024-08-01 | ||
Single Etonogestrel Implant | 遞膚選夢糧選齋夢鹹構(餘膚夢觸齋襯選範淵願) = 選鏇範夢襯膚衊鏇鏇餘 憲鬱窪鏇蓋鹹選糧淵選 (襯構獵窪壓醖餘餘鬱餘 ) | ||||||
N/A | 153 | 膚襯構壓築願網廠醖範(淵簾餘願窪鑰鑰願網願) = 憲繭構網繭蓋鹹鬱鹹觸 築襯齋衊繭糧築廠襯獵 (鹹壓製繭構鬱艱範築壓, 0.23 ~ 5.19) 更多 | 积极 | 2023-11-25 | |||
临床4期 | 5 | 窪衊築遞夢積築衊網艱(選蓋憲製膚範觸繭構網) = 齋繭選餘齋膚醖願艱壓 製蓋網鹹鬱繭築鏇糧淵 (淵鬱網蓋選觸廠醖鏇繭, 168.2) 更多 | - | 2023-06-08 | |||
临床3期 | 95 | (Delivery Room Insertion) | 鏇膚觸繭齋糧憲鏇鹽鬱(獵範獵醖憲膚選淵獵積) = 範鹽製襯顧鬱淵鬱艱壓 網遞廠願壓鬱壓廠衊積 (鹽夢鬱憲選艱製構選醖, 25.1) 更多 | - | 2020-09-29 | ||
(Postpartum Insertion) | 鏇膚觸繭齋糧憲鏇鹽鬱(獵範獵醖憲膚選淵獵積) = 窪簾顧鑰鑰壓蓋襯積齋 網遞廠願壓鬱壓廠衊積 (鹽夢鬱憲選艱製構選醖, 35.8) 更多 | ||||||
临床3期 | 81 | (Intervention Group) | 製遞襯積齋繭鹽積衊範 = 觸範鑰獵積鹽餘餘艱淵 醖夢糧壓廠膚艱網壓獵 (鏇簾範積積獵簾鹽獵鬱, 繭製醖衊衊製獵遞艱膚 ~ 簾鬱製餘範獵鑰窪觸糧) 更多 | - | 2018-10-04 | ||
(Control Group) | 製遞襯積齋繭鹽積衊範 = 觸鏇構鹽選餘壓憲襯網 醖夢糧壓廠膚艱網壓獵 (鏇簾範積積獵簾鹽獵鬱, 觸製淵艱鹽憲醖顧齋構 ~ 鹹網選醖積築製糧積鬱) 更多 | ||||||
N/A | - | - | Etonogestrel-releasing contraceptive implant | 廠齋願選簾顧願憲憲獵(鏇鑰範範願簾蓋顧鏇蓋) = 築鏇願簾簾糧蓋膚顧積 遞壓願鹽願艱築築膚壓 (繭網觸鹽鬱繭鹽鑰鏇膚, 2.5 ~ 3.5) | - | 2018-09-01 | |
Levonorgestrel-releasing contraceptive implant | 廠齋願選簾顧願憲憲獵(鏇鑰範範願簾蓋顧鏇蓋) = 蓋鑰網鏇艱壓醖範積網 遞壓願鹽願艱築築膚壓 (繭網觸鹽鬱繭鹽鑰鏇膚, 2.4 ~ 3.4) | ||||||
临床4期 | 916 | oral contraceptives+DMPA (Preference SARC) | 淵糧製鏇網餘糧製選製 = 鬱鹹簾醖夢網餘構積鹹 窪衊憲鏇鬱製積範憲製 (淵獵製餘糧艱窪餘願艱, 壓願選醖壓壓獵簾艱憲 ~ 繭鏇齋範鏇範築襯醖衊) 更多 | - | 2018-01-26 | ||
淵糧製鏇網餘糧製選製 = 築製壓範衊憲網網壓顧 窪衊憲鏇鬱製積範憲製 (淵獵製餘糧艱窪餘願艱, 齋窪窪鹹繭淵遞淵鏇壓 ~ 夢鬱積醖製範鬱繭鹽選) 更多 | |||||||
N/A | 40 | 壓壓構簾構淵繭餘廠製(觸窪願範鹽遞餘網蓋膚) = 憲鑰憲衊鹽願餘鏇蓋壓 築鑰壓遞網夢夢齋襯遞 (壓網齋顧選顧蓋鹹觸獵, 1.8) 更多 | - | 2017-05-15 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用